CAJ | 학술논문

目的：评价双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝炎的临床疗效和安全性。方法将46例非酒精性脂肪性肝炎随机分为对照组和治疗组。对照组口服复方甘草酸苷片，3次/d，3片/次；治疗组在对照组基础上加服双歧杆菌三联活菌胶囊2次/d，每次840 mg。疗程均为12周。观察患者治疗前及治疗后临床症状、血常规、尿常规和肝肾功能、血糖、血脂及检测血清内毒素水平变化。结果治疗后，治疗组临床症状缓解的有效率较对照组高（P<0.05）；2组ALT、AST和GGT均较治疗前降低（P均<0.05），但2组间差异无统计学意义；2组内毒素均较治疗前降低（P<0.05），且治疗组降低幅度大于对照组（P<0.05）。结论双歧杆菌三联活菌胶囊治疗可有效改善非酒精性脂肪性肝炎患者临床症状及内毒素水平，无不良反应。
목적：평개쌍기간균삼련활균효낭치료비주정성지방성간염적림상료효화안전성。방법장46례비주정성지방성간염수궤분위대조조화치료조。대조조구복복방감초산감편，3차/d，3편/차；치료조재대조조기출상가복쌍기간균삼련활균효낭2차/d，매차840 mg。료정균위12주。관찰환자치료전급치료후림상증상、혈상규、뇨상규화간신공능、혈당、혈지급검측혈청내독소수평변화。결과치료후，치료조림상증상완해적유효솔교대조조고（P<0.05）；2조ALT、AST화GGT균교치료전강저（P균<0.05），단2조간차이무통계학의의；2조내독소균교치료전강저（P<0.05），차치료조강저폭도대우대조조（P<0.05）。결론쌍기간균삼련활균효낭치료가유효개선비주정성지방성간염환자림상증상급내독소수평，무불량반응。
Objective To evaluate the efficacy and safety of bifidobacterium triple viable capsule in treatment of non-alcoholic steatohepatitis (NASH). Methods Forty-six NASH patients were randomized into a treatment group and a control group. The patients in the control group only received compound glycyrrhizin, 3 pills each time, 3 times daily for 12 weeks and patients in treatment group received bifidobacterium triple viable capsules, 840 mg each time, twice daily for 12 weeks, in addition to the administration of com-pound glycyrrhizin. Clinical symptoms, blood biochemistry indicators, liver and kidney function and serum endotoxin level were observed before and after treatment. Results After therapy, the clinical symptoms of the treatment group were ameliorated more efficiently than those of the control group (P<0.05). Compared with pre-therapy, the levels of ALT, AST and GGT of the two groups post-therapy decreased significantly (P<0.05), but the differences were not significant between the two groups. Compared with pre-therapy, the serum endotoxin level of the two groups decreased significantly (P<0.05), and the variation of the serum endotoxin level between pre-therapy and post-therapy in the treatment group was significantly greater than that in the control group (P<0.05). Conclusions Bifidobacterium triple viable capsule is effective in relieving the clinical symptoms and decreasing the serum endotoxin level in NASH patients. No adverse reaction are found during therapy.